Growth-oriented investor and operating executive with experience sourcing and scaling technology and healthcare businesses across North America and Europe. Christopher Griffith brings expertise in corporate strategy, M&A execution and board-level governance, focusing on SaaS, fintech and healthcare services. Prior roles span investments, operating leadership and advisory work; holds a graduate business degree and is active in venture and private equity deal syndication.
Growth-oriented investor and operating executive with experience sourcing and scaling technology and healthcare businesses across North America and Europe. Christopher Griffith brings expertise in corporate strategy, M&A execution and board-level governance, focusing on SaaS, fintech and healthcare services. Prior roles span investments, operating leadership and advisory work; holds a graduate business degree and is active in venture and private equity deal syndication.
Adopts a growth-oriented, operationally grounded investment approach focused on SaaS, fintech and healthcare services across North America and Europe. Prefers founder-led companies where active board engagement, strategic M&A and scalable go-to-market execution accelerate value creation. Allocates capital to recurring-revenue models with unit-economics visibility, backing rounds that fund product-market fit and commercial scaling. Risk managed by stage diversification, deep due diligence, and hands-on operational involvement to de-risk execution over a 3–7 year horizon.
Adopts a growth-oriented, operationally grounded investment approach focused on SaaS, fintech and healthcare services across North America and Europe. Prefers founder-led companies where active board engagement, strategic M&A and scalable go-to-market execution accelerate value creation. Allocates capital to recurring-revenue models with unit-economics visibility, backing rounds that fund product-market fit and commercial scaling. Risk managed by stage diversification, deep due diligence, and hands-on operational involvement to de-risk execution over a 3–7 year horizon.
| Trades 2421 | Longs Won 1740/2421 71% | Profit Factor 9.12 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $444,825.05 |
| Average Win $133,296.71 | Best Trade (Mar 31) $9.06M | Sharpe Ratio -10.52 |
| Average Loss -$37,359.1 | Worst Trade (Dec 31) -$2.03M | Z-Score 13.25 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4m 2d | Expectancy $85,293.15 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 19,608 | 17,647 | 15,686 | 13,725 | 11,765 | 9,804 | 7,843 | 5,882 | 3,922 | 1,961 |